Travere Therapeutics, Inc. (TVTX) is a biopharmaceutical organization dedicated to determining, developing and commercializing therapies to enhance the lives of individuals suffering from rare, severe diseases. The company is based in San Diego, California, and was formerly known as Retrophin, Inc. It changed its name to Travere Therapeutics, Inc. in November 2020. The company was founded in 2010 and is listed on NASDAQ under the symbol "TVTX".
Travere Therapeutics specializes in identifying and bringing to market novel therapeutics that target the body's cellular metabolism. Their primary focus is conducting innovative research to discover treatments for rare diseases that currently have no effective therapy. The company's lead product candidate, sparsentan, is a potential therapeutic for the treatment of focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
The company has multiple clinical drug candidates and a rich product portfolio that cover a range of ailments including kidney disease, liver disease, and neurological disorders. Travere Therapeutics' robust research and development capabilities, coupled with a strategic use of partnerships and acquisitions, enable a steady pipeline of potential new therapies.
Apart from the pharmaceutical development process, Travere is also keen on patient advocacy, supporting and participating in initiatives that aim to improve the lives of those affected by rare diseases. The company believes that collaboration with patient communities is integral to understanding the unique challenges they face and to creating innovative solutions that address their needs.
Travere is known for its strong corporate governance that values transparency, integrity, and accountability. The company adheres to rigorous operational and ethical standards to ensure it can effectively deliver on its mission and create value for its shareholders.
In recent years, the company has been recognized in the biopharma industry for its leadership in rare disease research, dedication to patient advocacy, and commitment to corporate responsibility. Despite inevitable challenges and competition in the biopharmaceutical industry, Travere continues to strive unfazed, working towards their mission of transforming the lives of patients with unmet medical needs.
Travere Therapeutics, therefore, operates at the intersection of scientific innovation, medical advancement, and patient care, bridging the gap between the laboratory and the patient's bedside, and striving to bring hope and health to the rare disease community.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Travere Therapeutics (TVTX) is undergoing a significant leadership change with Bradley Campbell taking over as CEO and President in December 2026. This coincides with a USPTO Notice of Allowance for a FILSPARI patent, extending its protection for focal segmental glomerulosclerosis until October 2037. These developments raise questions about the company's strategy for balancing execution risk with protecting a key asset, especially given its existing approvals for IgA nephropathy and FSGS.
Travere Therapeutics announced that President and CEO Eric Dube will step down effective December 1, 2026. Bradley L. Campbell, former CEO of Amicus Therapeutics, has been appointed as his successor. Campbell's compensation package includes a $1 million base salary, substantial bonus eligibility, and approximately $16.5 million in inducement equity grants.
Travere Therapeutics announced it has received a US patent allowance for its kidney disease drug, FILSPARI. This development was reported by MT Newswires. The full article is behind a premium paywall.
Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026. The stock currently trades at a significant discount to analyst targets and fair value estimates, driven by the potential expansion of its drug Filspari's label to treat FSGS. While the company shows strong long-term shareholder returns, its future relies heavily on the success of Filspari, posing both opportunity and execution risks.
Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.
Travere Therapeutics (TVTX) stock has seen significant price gains, leading to questions about its current valuation relative to revenue. While the stock's P/S ratio is lower than the biotech industry average, a "Fair Ratio" model suggests it might be overvalued based on growth outlook, margins, size, and risk. Analysts present both bull and bear cases, focusing on FILSPARI's potential and reliance on the product, respectively.
Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.
An insider at Travere Therapeutics sold shares valued at $25,390,729, as reported in a recent SEC filing. The article, published on September 18, 2026, by MT Newswires, provides this specific transaction detail among other insider sales for the company. Travere Therapeutics is a biopharmaceutical firm focused on rare kidney and metabolic diseases.
The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The agency claims that several statements in the visual aid, intended for physicians, are misleading as they are not supported by clinical data. The FDA highlighted issues with claims regarding "kidney preservation," "complete remission of proteinuria," and the drug being "well tolerated," demanding a response from Travere Therapeutics within 15 working days.